Total Payments
$25,459
2024 Payments
$1,000
Companies
4
Transactions
39
Payment Breakdown by Category
Consulting$12,700 (49.9%)
Research$10,703 (42.0%)
Travel$1,569 (6.2%)
Food & Beverage$487.32 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $12,700 | 4 | 49.9% |
| Unspecified | $10,703 | 18 | 42.0% |
| Travel and Lodging | $1,569 | 7 | 6.2% |
| Food and Beverage | $487.32 | 10 | 1.9% |
Payments by Type
General
$14,756
21 transactions
Research
$10,703
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma Global Development | $22,403 | 21 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $2,042 | 16 | $0 (2019) |
| Astellas Pharma US Inc | $1,000 | 1 | $0 (2024) |
| Allergan Inc. | $13.75 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,000 | 1 | Astellas Pharma US Inc ($1,000) |
| 2023 | $8,154 | 8 | Astellas Pharma Global Development ($8,154) |
| 2022 | $8,100 | 1 | Astellas Pharma Global Development ($8,100) |
| 2021 | $198.26 | 2 | Astellas Pharma Global Development ($198.26) |
| 2020 | $976.83 | 5 | Astellas Pharma Global Development ($976.83) |
| 2019 | $1,407 | 11 | Merck Sharp & Dohme Corporation ($1,104) |
| 2018 | $4,028 | 2 | Astellas Pharma Global Development ($4,028) |
| 2017 | $1,594 | 9 | Merck Sharp & Dohme Corporation ($938.22) |
All Payment Transactions
39 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/03/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Infectious Diseases | ||||||
| 10/20/2023 | Astellas Pharma Global Development | Cresemba (Drug) | — | Cash or cash equivalent | $338.44 | Research |
| Study: A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants • Category: Infectious Diseases | ||||||
| 10/20/2023 | Astellas Pharma Global Development | Cresemba (Drug) | — | Cash or cash equivalent | $203.47 | Research |
| Study: A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants • Category: Infectious Diseases | ||||||
| 08/18/2023 | Astellas Pharma Global Development | Cresemba (Drug) | — | Cash or cash equivalent | $851.23 | Research |
| Study: A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants • Category: Infectious Diseases | ||||||
| 04/19/2023 | Astellas Pharma Global Development | Cresemba (Drug) | — | Cash or cash equivalent | $221.08 | Research |
| Study: A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants • Category: Infectious Diseases | ||||||
| 03/29/2023 | Astellas Pharma Global Development | Cresemba (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Infectious Diseases | ||||||
| 03/14/2023 | Astellas Pharma Global Development | Cresemba (Drug) | — | Cash or cash equivalent | $2,380.88 | Research |
| Study: Retrospective real world clinical and economic evaluation of a pediatric population treated with isavuconazole • Category: Infectious Diseases | ||||||
| 02/17/2023 | Astellas Pharma Global Development | Cresemba (Drug) | — | Cash or cash equivalent | $558.78 | Research |
| Study: Retrospective real world clinical and economic evaluation of a pediatric population treated with isavuconazole • Category: Infectious Diseases | ||||||
| 02/13/2023 | Astellas Pharma Global Development | Cresemba (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Infectious Diseases | ||||||
| 12/07/2022 | Astellas Pharma Global Development | Cresemba (Drug) | Consulting Fee | Cash or cash equivalent | $8,100.00 | General |
| Category: Infectious Diseases | ||||||
| 06/23/2021 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $99.13 | Research |
| Study: A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients • Category: HOSPITAL AND TRANSPLANT | ||||||
| 04/27/2021 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $99.13 | Research |
| Study: A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients • Category: HOSPITAL AND TRANSPLANT | ||||||
| 12/10/2020 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $59.83 | Research |
| Study: A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients • Category: HOSPITAL AND TRANSPLANT | ||||||
| 10/22/2020 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $129.57 | Research |
| Study: A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients • Category: HOSPITAL AND TRANSPLANT | ||||||
| 09/18/2020 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $199.43 | Research |
| Study: A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients • Category: HOSPITAL AND TRANSPLANT | ||||||
| 04/30/2020 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $399.00 | Research |
| Study: A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients • Category: HOSPITAL AND TRANSPLANT | ||||||
| 04/18/2020 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $189.00 | Research |
| Study: A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients • Category: HOSPITAL AND TRANSPLANT | ||||||
| 11/29/2019 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $289.45 | Research |
| Study: A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients • Category: INFECTIOUS DISEASES | ||||||
| 05/13/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $13.75 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/25/2019 | Merck Sharp & Dohme Corporation | ZINPLAVA (Biological) | Travel and Lodging | In-kind items and services | $209.25 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/25/2019 | Merck Sharp & Dohme Corporation | ZINPLAVA (Biological) | Travel and Lodging | Cash or cash equivalent | $84.65 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/25/2019 | Merck Sharp & Dohme Corporation | ZINPLAVA (Biological) | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/25/2019 | Merck Sharp & Dohme Corporation | ZINPLAVA (Biological) | Food and Beverage | In-kind items and services | $52.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/25/2019 | Merck Sharp & Dohme Corporation | ZINPLAVA (Biological) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/24/2019 | Merck Sharp & Dohme Corporation | ZINPLAVA (Biological) | Travel and Lodging | In-kind items and services | $336.60 | General |
| Category: INFECTIOUS DISEASE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| None | Astellas Pharma Global Development | $4,011 | 3 |
| Retrospective real world clinical and economic evaluation of a pediatric population treated with isavuconazole | Astellas Pharma Global Development | $2,940 | 2 |
| A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants | Astellas Pharma Global Development | $1,614 | 4 |
| A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients | Astellas Pharma Global Development | $976.83 | 5 |
| This publication is not related to a clinical study | Astellas Pharma Global Development | $673.14 | 1 |
| A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients | Astellas Pharma Global Development | $487.71 | 3 |
About Dr. Michael Neely, MD
Dr. Michael Neely, MD is a Pediatric Infectious Diseases healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1154429793.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Neely, MD has received a total of $25,459 in payments from pharmaceutical and medical device companies, with $1,000 received in 2024. These payments were reported across 39 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($12,700).
Ad
Practice Information
- Specialty Pediatric Infectious Diseases
- Location Los Angeles, CA
- Active Since 09/20/2006
- Last Updated 07/08/2007
- Taxonomy Code 2080P0208X
- Entity Type Individual
- NPI Number 1154429793
Products in Payments
- Cresemba (Drug) $17,910
- CRESEMBA (Drug) $5,493
- ZINPLAVA (Biological) $1,104
- ZERBAXA (Drug) $938.22
- AVYCAZ (Drug) $13.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Infectious Diseases Doctors in Los Angeles
La Shonda Spencer, M.d, M.D
Pediatric Infectious Diseases — Payments: $129,926
Pediatric Infectious Diseases $129,926
Dr. Jaime Deville, M.d, M.D
Pediatric Infectious Diseases — Payments: $46,535
Pediatric Infectious Diseases $46,535
James Cherry, M.d, M.D
Pediatric Infectious Diseases — Payments: $2,819
Pediatric Infectious Diseases $2,819
Dr. Paul Krogstad, M.d, M.D
Pediatric Infectious Diseases — Payments: $153.77
Pediatric Infectious Diseases $153.77
Jennifer Rathe, M.d, M.D
Pediatric Infectious Diseases — Payments: $124.98
Pediatric Infectious Diseases $124.98
Grace Aldrovandi, Md, MD
Pediatric Infectious Diseases — Payments: $121.36
Pediatric Infectious Diseases $121.36